Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Michèle Tubiana-Hulin"'
Autor:
Emmanuelle Menet, Véronique Becette, Michèle Tubiana-Hulin, Frédérique Spyratos, M. Briffod, Florence Lerebours
Publikováno v:
The Breast Journal. 17:121-128
Neo-adjuvant chemotherapy of breast cancer provides an opportunity to evaluate predictive factors at initial tumor biopsy. We evaluated these factors on cell blocks obtained by diagnostic fine-needle cytopuncture (FNC), with respect to tumor regressi
Autor:
Isabelle Caroff-Paraïso, Hernán Cortés-Funes, Conrad F. Slabber, Pierre Fumoleau, Farhat Ben Ayed, Mario Campone, Amina B. Taleb, A. S. Alberts, Jean-Christophe Pouget, Michèle Tubiana-Hulin, Stephen Chan
Publikováno v:
American Journal of Clinical Oncology. 32:375-380
A multicenter, open-label, phase 2 study evaluated the efficacy and safety of intravenous vinflunine as third-line treatment in patients with progressing metastatic breast cancer (MBC) after failure of anthracycline- and taxane-based chemotherapy.Fif
Autor:
Adam Brufsky, Matti Aapro, Theresa A. Guise, Robert E. Coleman, Jean-Jacques Body, Michèle Tubiana-Hulin, Peyman Hadji, Allan Lipton
Publikováno v:
Annals of Oncology. 19:1407-1416
Recent studies indicate that women with breast cancer are at increased risk of fracture compared with their age-matched peers. Current treatment guidelines are inadequate for averting fractures in osteopenic women, especially those receiving aromatas
Autor:
Jonas Bergh, Hervé Bonnefoi, Anne-Laure Nicoulaz, Pierre Farmer, Darlene R. Goldstein, Mauro Delorenzi, Maryse Fiche, David Cameron, Gaëtan MacGrogan, Véronique Becette, Cathrin Brisken, Michèle Tubiana-Hulin, Richard Iggo, Pierre Fumoleau, Denis Larsimont, Stephan Duss
Publikováno v:
Breast Cancer Research : BCR
Previous microarray studies on breast cancer identified multiple tumour classes, of which the most prominent, named luminal and basal, differ in expression of the estrogen receptor alpha gene (ER). We report here the identification of a group of brea
Autor:
Pierre Pouillart, Jean-Paul Guastalla, Moïse Namer, Eric Pujade-Lauraine, Pierre Fumoleau, Marc Buyse, Gilles Romieu, Michèle Tubiana-Hulin, Louis Mauriac, Pierre Kerbrat, Frédérique Penault-Llorca, Philippe Maillart, Véronique Diéras
Publikováno v:
Journal of Clinical Oncology. 22:4958-4965
Purpose This randomized, noncomparative, parallel-group study was designed to evaluate the pathologic complete response (pCR) rate of combined doxorubicin plus paclitaxel (AP) and doxorubicin plus cyclophosphamide (AC) as neoadjuvant chemotherapy in
Publikováno v:
Oncology. 66:185-191
The purpose of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of combined paclitaxel, epirubicin and cyclophosphamide in patients with metastatic breast cancer. The dose of paclitaxel was planned to be e
Autor:
G. Ganem, V. Lotz, Thomas Bachelot, M. Combe, J.-M. Vannetzel, L.R. De Ybarlucea, Véronique Diéras, P. Fumoleau, B. Bendahmane, Michèle Tubiana-Hulin, J.L. Misset
Publikováno v:
Annals of Oncology. 14:1623-1628
Background This study was conducted to assess the antitumour activity of docetaxel in combination with doxorubicin for neoadjuvant therapy of patients with breast cancer. Patients and methods Forty-eight women were treated with intravenous doxorubici
Autor:
Ivan Bièche, Michèle Tubiana-Hulin, Rosette Lidereau, Igor Girault, Frédérique Spyratos, Florence Lerebours, Sengül Tozlu
Publikováno v:
The Journal of Steroid Biochemistry and Molecular Biology. 82:323-332
Aromatase, the product of the CYP19 gene, plays a key role in androgenic steroids transformation into estrogens from various hormonal sensitive tissues. Thus, in situ expression of CYP19 has been suggested to be involved in breast tumor growth especi
Autor:
Ph. Chollet, Véronique Diéras, E. Gamelin, M. Spielmann, Laurent Zelek, Michel Marty, J.-M. Vannetzel, J.L. Misset, S. Mackenzie, N. Chouaki, Michèle Tubiana-Hulin, Stéphane Culine, Paul-Henri Cottu
Publikováno v:
Journal of Clinical Oncology. 20:2551-2558
PURPOSE: Phase II study evaluating efficacy and safety of combined oxaliplatin/fluorouracil (5-FU) in taxane-pretreated advanced and metastatic breast cancer (ABC) patients. PATIENTS AND METHODS: Sixty-four taxane- and anthracycline-pretreated (withi
Autor:
Michèle Tubiana-Hulin, Edelmira Phillips, Frédérique Spyratos, Viviane Le Doussal, Magali Ferrero-Poüs, Kamel Hacène, Martine Trassard
Publikováno v:
Cancer. 94:2151-2159
BACKGROUND Cell proliferation is a major determinant of the biologic behavior of breast carcinoma. MIB-1 monoclonal antibody is a promising tool for determining cell proliferation on routine histologic material. The objectives of this study were to c